2,5-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine | 1507171-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,5-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine
• 英文别名: 2,5-dichloro-N-[(4-methoxyphenyl)methyl]pyrimidin-4-amine
• CAS: 1507171-88-1
• 化学式: C₁₂H₁₁Cl₂N₃O
• mdl: MFCD23328978
• 分子量: 284.145
• InChiKey: WSFWEOJXUHQZSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-甲基-4-(6-氨基吡啶-3-基)哌嗪 、 2,5-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 生成 5-chloro-N⁴-(4-methoxybenzyl)-N²-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  Discovery and SARs of 5-Chloro-N⁴-phenyl-N²-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

  摘要：

  Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy. Herein, we describe our efforts toward the discovery of a series of 5-chloro-N-4-phenyl-N-2(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as dual CDK6 and 9 inhibitors. Intensive structural modifications lead to the identification of compound 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2. Further biological studies revealed that compound 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis. More importantly, compound 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment. Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.

  DOI：

  10.1021/acs.jmedchem.9b02121
• 作为产物：
  描述：

  2,4,5-三氯嘧啶 、 4-甲氧基苄胺 在 四丁基碘化铵 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 以74%的产率得到2,5-dichloro-N-(4-methoxybenzyl)pyrimidin-4-amine
  参考文献：
  名称：

  Discovery and SARs of 5-Chloro-N⁴-phenyl-N²-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

  摘要：

  Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy. Herein, we describe our efforts toward the discovery of a series of 5-chloro-N-4-phenyl-N-2(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as dual CDK6 and 9 inhibitors. Intensive structural modifications lead to the identification of compound 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2. Further biological studies revealed that compound 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis. More importantly, compound 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment. Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.

  DOI：

  10.1021/acs.jmedchem.9b02121

文献信息

• One-pot synthesis and antiproliferative activity of novel 2,4-diaminopyrimidine derivatives bearing piperidine and piperazine moieties
  作者：Wei-Feng Ma、Hai-Kui Yang、Meng-Jin Hu、Qian Li、Tian-Zhu Ma、Zhong-Zhen Zhou、Rui-Yuan Liu、Wen-Wei You、Pei-Liang Zhao

  DOI：10.1016/j.ejmech.2014.07.017

  日期：2014.9

  A series of novel 2,4-diaminopyrimidines containing piperidine and piperazine moieties were synthesized via an efficient one-pot methodology. The bioassay tests demonstrated that compounds 27 and 28 displayed much stronger antitumor activities against four human cancer cell lines (HepG2, A549, MDA-MB-231 and MCF-7) than positive control fluorouracil. Particularly, compound 28 showed a two-fold improvement compared to fluorouracil in inhibiting MDA-MB-231 and A549 cell proliferation with IC50 values of 7.46 and 12.78 μM, respectively. Further flow-activated cell sorting analysis revealed that the most promising compound 28 displayed a significant effect on G2/M cell-cycle arrest in a dose-dependent manner in MDA-MB-231 cells.
• Discovery and SARs of 5-Chloro-<i>N</i>⁴-phenyl-<i>N</i>²-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity
  作者：Yang Wang、Xing Chen、Yaoyao Yan、Xiaochen Zhu、Mingming Liu、Xinhua Liu

  DOI：10.1021/acs.jmedchem.9b02121

  日期：2020.3.26

  Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy. Herein, we describe our efforts toward the discovery of a series of 5-chloro-N-4-phenyl-N-2(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as dual CDK6 and 9 inhibitors. Intensive structural modifications lead to the identification of compound 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2. Further biological studies revealed that compound 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis. More importantly, compound 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment. Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.